Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer
Mené en Corée entre 2010 et 2016 sur 184 patientes atteintes d'un cancer de l'ovaire de stade III ou IV (durée médiane de suivi : 69,4 mois), cet essai randomisé multicentrique évalue l'intérêt, du point de vue de la survie sans progression et de la survie globale, d'ajouter une chimiothérapie intrapéritonéale hyperthermique à une chirurgie de cytoréduction primaire ou d'intervalle
Hyperthermic intraperitoneal chemotherapy (HIPEC) has been a treatment modality of interest for more than 40 years; initially focusing on the treatment of gastrointestinal malignant tumors, HIPEC was subsequently used to treat a classic peritoneal malignant tumor—epithelial ovarian cancer (EOC). Intraperitoneal chemotherapy for advanced EOC has been a focus of research and debate for more than 30 years. Support peaked with the publication of the Gynecologic Oncology Group (GOG) 172 trial, the seventh randomized clinical trial comparing standard intravenous chemotherapy with intraperitoneal chemotherapy, and a rare National Cancer Institute clinical announcement in 2006 and nadired with the publication of the negative findings of GOG-252.
JAMA Surgery 2022